About Alvotech
Alvotech (NASDAQ:ALVO) specializes in the development and manufacture of biosimilar pharmaceuticals, aiming to improve global access to high-quality biologic medicines. The company is notably focused on a diversified portfolio that includes biosimilars across a variety of therapeutic areas. With a strong commitment to innovation and sustainability, Alvotech’s mission is to lead the biosimilar space by delivering affordable and effective biologic treatments to patients worldwide. The company's strategic initiatives emphasize cutting-edge research, robust development programs, and strategic global partnerships to ensure high standards of quality and accessibility. Through these efforts, Alvotech not only aims to meet current healthcare needs but also to anticipate and address future challenges within the biosimilar market.
Snapshot
Operations
Produtos e/ou serviços de Alvotech
- High-concentration adalimumab biosimilar, targeting chronic conditions like arthritis and psoriasis, represents a major initiative aiming at providing affordable biologic treatment options.
- A pipeline of biosimilars in various stages targeting autoimmune diseases, oncology, and ophthalmology to expand global access to life-saving treatments.
- Partnership with Teva Pharmaceuticals to commercialize biosimilars in the U.S., enhancing the reach and impact of biologic treatments across a key market.
- Advanced manufacturing facility in Iceland, leveraging cutting-edge technology to produce high-quality biopharmaceuticals efficiently and sustainably.
- Strong investment in research and development focused on biosimilar and novel biologic therapies, underlining commitment to innovation in biopharmaceuticals.
- Global strategic collaborations for the development, manufacturing, and commercialization of biosimilars, aiming to improve patient access to affordable biologics worldwide.
equipe executiva do Alvotech
- Mr. Vilhelm Robert WessmanFounder, CEO & Executive Chairman
- Ms. Linda JonsdottirChief Financial Officer
- Mr. Joseph E. McClellanChief Operating Officer
- Mr. Benedikt StefanssonVice President of Investor Relations & Global Communications
- Ms. Tanya ZharovGeneral Counsel
- Ms. Sarah MacleodHead of Global Communications
- Ms. Kathryn GunnarssonSenior Vice President of Global Talent & People Experience
- Mr. Anthony M. Maffia IIIChief Quality & Regulatory Officer
- Dr. Balaji Venkataramanan Prasad M.D.Chief Strategy Officer
- Mr. Johann G. JohannssonExecutive Vice President of Capital Markets and M&A